Zolgensma denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for zolgensma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Zolgensma

Zolgensma (onasemnogene abeparvovec) is a high-cost gene therapy for spinal muscular atrophy (SMA), and UnitedHealthcare requires prior authorization (PA) before it will be covered. A prior-auth-required denial means either that authorization was not obtained before treatment was initiated, or that an authorization request was submitted but denied because the documentation did not satisfy UHC's clinical criteria.

If treatment has already been administered without a PA, you may be pursuing a retrospective (post-service) appeal; if the PA was submitted and denied before treatment, this is a prospective appeal. The process differs slightly, but the documentation requirements are largely the same. Both paths are legally available to you.

## Your Appeal Rights

• Internal appeal: Submit a written internal appeal within the deadline on the denial letter. Under ERISA §503 (employer plans), you are entitled to a full-and-fair review with access to the criteria the insurer applied.
• External review (ACA §2719): After an adverse internal decision, independent external review is available. The standard window is up to four months from the final internal denial. If the patient's condition is urgent, request expedited external review — reviewers must respond within 72 hours.
• Retroactive authorization requests: If treatment was given in an emergency or urgent context without time to obtain PA, document the clinical urgency carefully; many plans allow retroactive PA under those circumstances.

## Documentation to Gather

1. Genetic confirmation of SMA — laboratory report with SMN1 mutation and SMN2 copy number, ordered by the treating neurologist. 2. Disease type and clinical staging — neurologist notes documenting SMA type, age at symptom onset, current functional status, and disease trajectory. 3. Motor and pulmonary assessments — dated clinical evaluations using standard functional scales as recorded in the chart. 4. Prior treatment history — complete log of any prior or current SMA therapies, with dates and documented clinical responses. 5. Prescriber PA letter — a detailed letter from the treating pediatric neurologist or neuromuscular specialist explaining medical necessity, citing the FDA-approved prescribing information and applicable professional society guidance. 6. Treating facility credentials — documentation that the administering center has the qualifications required by UHC's policy (often a specialized center requirement for gene therapy).

## Criteria-Mapping Structure

Download the current UnitedHealthcare prior authorization criteria for Zolgensma and the FDA-approved prescribing label. Address each criterion explicitly:

| PA Criterion | Supporting Documentation | |---|---| | Confirmed SMA genetic diagnosis | Lab report, [date] | | SMA type and clinical presentation | Neurologist clinic note, [date] | | Age / weight / disease stage per label | Chart measurement with date | | Prescriber specialty requirement | Treating physician credentials | | Administering facility requirements | Infusion center documentation | | Absence of disqualifying factors per label | Prescriber attestation, [date] |

For the PA submission or appeal, organize the documentation so every criterion has a named, dated exhibit. UHC reviewers process large volumes of requests; a submission that mirrors the policy checklist point-by-point is more likely to be approved on first review and reduces the chance of a delay on administrative grounds.